# Evaluation of Efficacy and Safety of ATB-1011+ATB-1012 Co-administration for Essential Hypertension and Type II Diabetes

> **NCT05573477** · PHASE3 · UNKNOWN · sponsor: **Autotelicbio** · enrollment: 248 (estimated)

## Conditions studied

- Essential Hypertension
- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** ATB-1011
- **DRUG:** ATB-1012
- **DRUG:** ATB-1013
- **DRUG:** ATB-1011 placebo
- **DRUG:** ATB-1012 placebo
- **DRUG:** ATB-1013 placebo

## Key facts

- **NCT ID:** NCT05573477
- **Lead sponsor:** Autotelicbio
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-11-16
- **Primary completion:** 2024-01
- **Final completion:** 2024-06
- **Target enrollment:** 248 (ESTIMATED)
- **Last updated:** 2023-02-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05573477

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05573477, "Evaluation of Efficacy and Safety of ATB-1011+ATB-1012 Co-administration for Essential Hypertension and Type II Diabetes". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05573477. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*